|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
CA2618218C
(en)
|
2005-07-21 |
2015-06-30 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of mek
|
|
US7919598B2
(en)
*
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
ES2320955B1
(es)
|
2007-03-02 |
2010-03-16 |
Laboratorios Almirall S.A. |
Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
|
|
WO2008115890A2
(en)
|
2007-03-19 |
2008-09-25 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
ES2329639B1
(es)
|
2007-04-26 |
2010-09-23 |
Laboratorios Almirall S.A. |
Nuevos derivados de 4,8-difenilpoliazanaftaleno.
|
|
US8569378B2
(en)
|
2007-07-20 |
2013-10-29 |
Toshiyuki Sakai |
p27 protein inducer
|
|
ES2456966T3
(es)
|
2007-11-12 |
2014-04-24 |
Takeda Pharmaceutical Company Limited |
Inhibidores de MAPK/ERK cinasa
|
|
WO2009146034A2
(en)
*
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
EP2108641A1
(en)
|
2008-04-11 |
2009-10-14 |
Laboratorios Almirall, S.A. |
New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
|
|
EP2113503A1
(en)
|
2008-04-28 |
2009-11-04 |
Laboratorios Almirall, S.A. |
New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
RU2393157C1
(ru)
*
|
2008-10-06 |
2010-06-27 |
Андрей Александрович Иващенко |
2-АЛКИЛАМИНО-3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
|
RU2399621C2
(ru)
*
|
2008-10-14 |
2010-09-20 |
Андрей Александрович Иващенко |
ЗАМЕЩЕННЫЕ 2-АЛКИЛАМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
WO2010059658A1
(en)
|
2008-11-20 |
2010-05-27 |
Glaxosmithkline Llc |
Chemical compounds
|
|
JP5651125B2
(ja)
|
2008-12-10 |
2015-01-07 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
|
|
MX2011010079A
(es)
*
|
2009-03-26 |
2011-10-10 |
Mapi Pharma Ltd |
Proceso para la preparacion de alogliptina.
|
|
CN101619063B
(zh)
*
|
2009-06-02 |
2011-08-10 |
华中师范大学 |
具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
|
|
WO2011031308A1
(en)
*
|
2009-09-09 |
2011-03-17 |
Cytokinetics, Incorporated |
Novel combinations
|
|
MX2012003546A
(es)
*
|
2009-09-23 |
2012-09-07 |
Glaxosmithkline Llc |
Combinacion.
|
|
US20120283278A1
(en)
*
|
2009-09-23 |
2012-11-08 |
Melissa Dumble |
Combination
|
|
MX2012003779A
(es)
*
|
2009-09-28 |
2012-06-01 |
Glaxosmithkline Llc |
Combinacion.
|
|
EA022982B1
(ru)
*
|
2009-10-08 |
2016-04-29 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Комбинация для лечения рака или предраковых синдромов
|
|
DK4159217T3
(da)
|
2009-10-16 |
2024-08-12 |
Novartis Ag |
Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
|
|
CA2777304A1
(en)
|
2009-10-21 |
2011-04-28 |
Marion Hitchcock |
Substituted benzosulphonamides
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
WO2011047796A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
AU2010322105B2
(en)
*
|
2009-11-17 |
2014-05-08 |
Novartis Ag |
Combination
|
|
ES2576061T3
(es)
|
2010-02-25 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
|
|
RU2421456C1
(ru)
*
|
2010-02-26 |
2011-06-20 |
Общество С Ограниченной Ответственностью "Инновационная Фармацевтика" |
ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИН-2,6-ДИАМИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
|
|
MX343368B
(es)
|
2010-03-09 |
2016-11-01 |
The Broad Inst Inc * |
Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
|
|
UY33288A
(es)
*
|
2010-03-25 |
2011-10-31 |
Glaxosmithkline Llc |
Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
|
|
CA2794153C
(en)
|
2010-03-25 |
2018-01-02 |
Glaxosmithkline Llc |
Substituted indoline derivatives as perk inhibitors
|
|
MX2012011912A
(es)
*
|
2010-04-13 |
2012-11-16 |
Novartis Ag |
Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
|
|
ES2530755T3
(es)
|
2010-05-21 |
2015-03-05 |
Glaxosmithkline Llc |
Terapia de combinación para el tratamiento del cáncer
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
EP2608790A4
(en)
*
|
2010-08-26 |
2014-04-02 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
|
|
US9045429B2
(en)
|
2010-10-29 |
2015-06-02 |
Bayer Intellectual Property Gmbh |
Substituted phenoxypyridines
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
US20130217710A1
(en)
*
|
2010-11-05 |
2013-08-22 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods for treating cancer
|
|
EP2640390A4
(en)
*
|
2010-11-17 |
2014-08-06 |
Glaxosmithkline Ip No 2 Ltd |
METHODS OF TREATING CANCER
|
|
KR20130116291A
(ko)
*
|
2010-11-19 |
2013-10-23 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
Braf 억제제를 이용한 치료 방법
|
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產（第二）有限公司 |
新穎醫藥組成物
|
|
ES2603479T3
(es)
|
2010-12-20 |
2017-02-27 |
Novartis Ag |
Terapia de combinación que comprende gemcitabina para el tratamiento de cáncer pancreático
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
WO2013019620A2
(en)
*
|
2011-07-29 |
2013-02-07 |
Glaxosmithkline Llc |
Method of treating cancer using combination of braf inhibitor, mek inhibitor, and anti-ctla-4 antibody
|
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
WO2013066483A1
(en)
|
2011-08-31 |
2013-05-10 |
Novartis Ag |
Synergistic combinations of pi3k- and mek-inhibitors
|
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
|
JP6431770B2
(ja)
|
2012-03-14 |
2018-11-28 |
ルピン・リミテッド |
Ｍｅｋインヒビターとしてのヘテロシクリル化合物
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
UA125503C2
(uk)
|
2012-06-13 |
2022-04-13 |
Інсайт Холдинґс Корпорейшн |
Заміщені трициклічні сполуки як інгібітори fgfr
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
PT2892535T
(pt)
|
2012-09-04 |
2021-12-15 |
Novartis Ag |
Método de tratamento adjuvante do cancro
|
|
CN104812391A
(zh)
*
|
2012-10-25 |
2015-07-29 |
葛兰素史克公司 |
组合
|
|
PL2925366T3
(pl)
|
2012-11-29 |
2018-08-31 |
Novartis Ag |
Kombinacje farmaceutyczne
|
|
IN2015DN04094A
(enExample)
|
2012-11-30 |
2015-10-09 |
Glaxosmithkline Llc |
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
US20150342957A1
(en)
|
2013-01-09 |
2015-12-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination
|
|
WO2014133071A1
(ja)
|
2013-02-27 |
2014-09-04 |
第一三共株式会社 |
Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
|
|
MY181497A
(en)
|
2013-04-19 |
2020-12-23 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
UY35587A
(es)
|
2013-05-28 |
2014-12-31 |
Glaxosmithkline Ip No 2 Ltd |
Método de tratamiento del cáncer
|
|
WO2014195852A1
(en)
|
2013-06-03 |
2014-12-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
|
CA2927635C
(en)
*
|
2013-10-25 |
2021-07-20 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
|
|
WO2015059677A1
(en)
|
2013-10-26 |
2015-04-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer
|
|
WO2015081566A1
(zh)
*
|
2013-12-06 |
2015-06-11 |
杭州普晒医药科技有限公司 |
曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
|
|
JP2017500307A
(ja)
|
2013-12-12 |
2017-01-05 |
ノバルティス アーゲー |
がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP2913048A1
(en)
*
|
2014-02-27 |
2015-09-02 |
ratiopharm GmbH |
Pharmaceutical composition comprising trametinib
|
|
CA2936962C
(en)
|
2014-03-14 |
2024-03-05 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
CA2954508A1
(en)
|
2014-07-15 |
2016-01-21 |
Genentech, Inc. |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
WO2016009306A1
(en)
|
2014-07-15 |
2016-01-21 |
Lupin Limited |
Heterocyclyl compounds as mek inhibitors
|
|
WO2016035008A1
(en)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Pyridopyrimidine derivatives as mek inhibitors
|
|
CA2960824A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
|
EP3662903A3
(en)
|
2014-10-03 |
2020-10-14 |
Novartis AG |
Combination therapies
|
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
|
CA2964367C
(en)
|
2014-10-14 |
2024-01-30 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
CR20170390A
(es)
|
2015-02-20 |
2017-10-23 |
Incyte Holdings Corp |
Heterociclos biciclicos como inhibidores de fgfr
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
CZ2015278A3
(cs)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Krystalické formy trametinibu
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
CA2992221C
(en)
|
2015-08-28 |
2023-06-27 |
Novartis Ag |
Mdm2 inhibitors and combinations thereof
|
|
CN108135905A
(zh)
|
2015-08-28 |
2018-06-08 |
诺华股份有限公司 |
用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合
|
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
|
RU2605400C1
(ru)
*
|
2015-11-13 |
2016-12-20 |
ЗАО "Р-Фарм" |
ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
KR102793563B1
(ko)
|
2016-03-04 |
2025-04-11 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양 치료용 제제 및 조성물
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
EP3515446B1
(en)
|
2016-09-19 |
2023-12-20 |
Novartis AG |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
RU2627692C1
(ru)
*
|
2016-10-10 |
2017-08-10 |
Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") |
N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
|
|
CN107970246B
(zh)
*
|
2016-10-21 |
2020-08-28 |
中山大学 |
非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
ES2848720T3
(es)
|
2016-11-25 |
2021-08-11 |
Genuv Inc |
Composición para promover la diferenciación y la protección de células madre neurales y método para inducir la regeneración neural utilizando la misma
|
|
BR112019011365A2
(pt)
|
2016-12-01 |
2019-10-22 |
Glaxosmithkline Ip Dev Ltd |
métodos para tratar câncer
|
|
CN110494166B
(zh)
|
2017-05-02 |
2022-11-08 |
诺华股份有限公司 |
组合疗法
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
MY203305A
(en)
|
2018-03-19 |
2024-06-23 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
WO2019180141A1
(en)
|
2018-03-23 |
2019-09-26 |
Bayer Aktiengesellschaft |
Combinations of rogaratinib
|
|
RU2020135055A
(ru)
|
2018-03-30 |
2022-05-05 |
Новартис Аг |
Тройная фармацевтическая комбинация, включающая дабрафениб, траметиниб и ингибитор erk
|
|
EP3560516A1
(en)
|
2018-04-27 |
2019-10-30 |
Bergen Teknologioverforing AS |
Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof
|
|
PE20210919A1
(es)
|
2018-05-04 |
2021-05-19 |
Incyte Corp |
Sales de un inhibidor de fgfr
|
|
BR112020022392A2
(pt)
|
2018-05-04 |
2021-02-02 |
Incyte Corporation |
formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
|
|
EP3802609A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CN112867803A
(zh)
|
2018-10-16 |
2021-05-28 |
诺华股份有限公司 |
单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
|
|
CN109320513B
(zh)
*
|
2018-11-09 |
2021-03-16 |
安庆奇创药业有限公司 |
一种合成曲美替尼的方法
|
|
CN113473986B
(zh)
*
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
CN113473978B
(zh)
|
2018-11-20 |
2025-03-28 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病氰基芳烃-苯胺化合物
|
|
MA54741A
(fr)
|
2018-11-20 |
2021-11-24 |
Nflection Therapeutics Inc |
Composés thiényl-aniline destinés au traitement d'affections de la peau
|
|
CN113613724B
(zh)
|
2018-11-30 |
2024-11-08 |
葛兰素史克知识产权开发有限公司 |
可用于hiv疗法的化合物
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EP3920932A4
(en)
*
|
2019-02-06 |
2022-10-19 |
Aurobindo Pharma Limited |
METHOD FOR PREPARING AN ACETIC ACID SOLVATE OF TRAMETINIB
|
|
US12479817B2
(en)
|
2019-02-15 |
2025-11-25 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222345B2
(en)
|
2019-02-15 |
2022-11-17 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
CA3136888A1
(en)
|
2019-04-19 |
2020-10-22 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti- psma/cd3 antibody
|
|
KR102881316B1
(ko)
|
2019-05-13 |
2025-11-05 |
노파르티스 아게 |
암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TW202114994A
(zh)
*
|
2019-07-29 |
2021-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法
|
|
WO2021018941A1
(en)
|
2019-07-31 |
2021-02-04 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treating cancer
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
GEP20247679B
(en)
|
2019-10-14 |
2024-10-10 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
PE20221504A1
(es)
|
2019-12-04 |
2022-09-30 |
Incyte Corp |
Derivados de un inhibidor de fgfr
|
|
JP7720840B2
(ja)
|
2019-12-04 |
2025-08-08 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式複素環
|
|
JP2023506958A
(ja)
|
2019-12-20 |
2023-02-20 |
ノバルティス アーゲー |
骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
|
|
EP4087868A4
(en)
*
|
2020-01-08 |
2024-03-20 |
Icahn School of Medicine at Mount Sinai |
SMALL MOLECULAR MODULATORS FOR KSR-BONDED MEK
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202140029A
(zh)
|
2020-02-18 |
2021-11-01 |
瑞士商諾華公司 |
用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
|
|
JPWO2021206167A1
(enExample)
|
2020-04-10 |
2021-10-14 |
|
|
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
|
CN115551509A
(zh)
|
2020-05-12 |
2022-12-30 |
诺华股份有限公司 |
包含craf抑制剂的治疗组合
|
|
US20230212164A1
(en)
*
|
2020-06-02 |
2023-07-06 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230321110A1
(en)
|
2020-08-31 |
2023-10-12 |
Novartis Ag |
Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
AU2021392040A1
(en)
|
2020-12-02 |
2023-06-29 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
AU2022210800A1
(en)
|
2021-01-25 |
2023-08-10 |
Ikena Oncology, Inc. |
Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
|
|
CA3210246A1
(en)
|
2021-01-28 |
2022-08-04 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
CN117794929A
(zh)
|
2021-02-02 |
2024-03-29 |
法国施维雅药厂 |
选择性bcl-xl protac化合物及使用方法
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
TWI825637B
(zh)
*
|
2021-03-31 |
2023-12-11 |
美商輝瑞股份有限公司 |
啶－１，６（２ｈ，７ｈ）－二酮
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117479942A
(zh)
|
2021-04-09 |
2024-01-30 |
勃林格殷格翰国际有限公司 |
抗癌疗法
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4323066A1
(en)
*
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2022234409A1
(en)
|
2021-05-05 |
2022-11-10 |
Novartis Ag |
Compounds and compositions for the treatment of mpnst
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
TW202313611A
(zh)
|
2021-06-09 |
2023-04-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之三環雜環
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
TW202313041A
(zh)
|
2021-06-09 |
2023-04-01 |
瑞士商諾華公司 |
包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
CN119156457A
(zh)
|
2022-03-02 |
2024-12-17 |
诺华有限公司 |
用于癌症治疗的精准疗法
|
|
CN114573582B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
|
|
CN114605408B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
|
|
CN114573581B
(zh)
*
|
2022-03-30 |
2023-09-01 |
沈阳药科大学 |
5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
|
|
CN114456166B
(zh)
*
|
2022-03-30 |
2023-06-16 |
沈阳药科大学 |
5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
|
|
AU2023273734A1
(en)
|
2022-05-20 |
2024-12-12 |
Les Laboratoires Servier |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
KR20250027281A
(ko)
|
2022-05-20 |
2025-02-25 |
노파르티스 아게 |
Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법
|
|
CN114853754B
(zh)
*
|
2022-05-23 |
2023-04-18 |
云白药征武科技(上海)有限公司 |
一种硫代酰胺衍生物及其制备方法和应用
|
|
TW202404581A
(zh)
|
2022-05-25 |
2024-02-01 |
美商醫肯納腫瘤學公司 |
Ｍｅｋ抑制劑及其用途
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
IL322700A
(en)
|
2023-03-10 |
2025-10-01 |
Novartis Ag |
Antibody-drug conjugates that inhibit fennerase and methods of using them
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
WO2025132408A2
(en)
|
2023-12-21 |
2025-06-26 |
Synthon B.V. |
Solvates of trametinib
|
|
WO2025132190A1
(en)
|
2023-12-22 |
2025-06-26 |
Synthon B.V. |
A process for making trametinib
|
|
WO2025146444A1
(en)
|
2024-01-03 |
2025-07-10 |
Bayer Aktiengesellschaft |
Darolutamide in combination with braf and mek inhibitors for melanoma treatment
|
|
CN120441478A
(zh)
*
|
2024-02-07 |
2025-08-08 |
成都赜灵生物医药科技有限公司 |
一种六元内酰胺类化合物及其应用
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
CN118121604B
(zh)
*
|
2024-05-07 |
2024-06-25 |
四川成都中农大现代农业产业研究院 |
表没食子儿茶素没食子酸酯的组合物及其作为铜离子载体抗肝癌增敏剂的用途
|